SPONSOR
Shanghai Henlius Biotech
Total Trials
4
Recruiting
4
Phases
Phase 2, EARLY_Phase 1
Conditions studied: Carcinoma, HepatocellularNasopharyngeal Carcinoma (NPC)Advanced/Metastatic Solid TumorsNSCLCCervical CancerOvarian Cancer
NCT06349980 Phase 2
Recruiting
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Carcinoma, Hepatocellular
NCT06839066 Phase 2
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Nasopharyngeal Carcinoma (NPC)
NCT07274813 EARLY_Phase 1
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
NCT06769152 Phase 2
Recruiting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Cervical Cancer